AFG Venture Group Dispatches

Corporate advisory and consultancy in Australia, South East Asia and India.

Archive for Health and Life Sciences

CEDA report – ‘Healthcare: Reform or ration’

CEDA – the Committee for Economic Development of Australia – is a national, independent, member-based organisation providing thought leadership and policy perspectives on the economic and social issues affecting Australia. CEDA recently released its policy perspective entitled ‘Healthcare: Reform or ration’ available here: http://www.ceda.com.au/media/302619/healthcarefinal1.pdf The Executive Summary discusses increase in health expenditure linked to increased level of utilisation […]

International Trends In Healthcare – The Consumer View of Healthcare In 2040

Dr Liz Paslawsky (formerley Gale), Phd, M.H.A, H1, BSc Company CEO, Dr Liz Paslawsky & Associates Extracts from a conference paper given in Brussels at the International Design and Health Conference – October 2010. The conference paper was in two parts. The first was the patient’s view of health care in 2040. The second was […]

What Is The Future For The Big Pharma Model?

Phil Kearney Director of Licensing & External Research, Merck, Sharp & Dohme The 2010 Pharmaceutical R&D Factbook, compiled by CMR International, painted a gloomy picture of the global pharmaceuticals sector. Most notable was the finding that new drugs launched within the last five years accounted for less than 7 percent of industry sales in 2009, […]

Global Trends in Health

Anushka Patel Senior Director and Chair of the Chronic & Critical Conditions Theme, The George Institute for Global Health What causes most disease and ill-health in China and India? Most people would immediately identify infections such as cholera, typhoid, tuberculosis, malaria and HIV, along with problems relating to maternal and child health. These diseases of […]

Will The IPO Market Open For Australian Biotechs in 2011?

David R Blake Co-Editor, Bioshares For some ASX listed biotech the last 12 months have been positive beyond belief. Stem cell company Mesoblast saw its capitalisation rocket from $286 million at the end of the March quarter 2010 to a little over $2 billion as at March 31, 2010. Its closing share price on that […]